TaiwanPlus Features Namewee and ABAO’s Music-Creation Journey on Its Indie Music Docuseries, “Road to Legacy”
TaiwanPlus, a new global English-language video streaming platform, launches a 2022 TaiwanPlus Original Series titled “Road to Legacy,” which is a 10-episode docuseries detailing the journey to fame of these 10 bands in Taiwan. On January 17, 2022, TaiwanPlus holds the world premiere at Legacy Taipei, with the docuseries launched exclusively and free to stream worldwide via www.TaiwanPlus.com on the same day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005075/en/
The TaiwanPlus Original Series will be released in three installments, kicking off with the episodes on Tizzy Bac, 88BALAZ and Nighteentael on January 17th. (Graphic: Business Wire)
Since its inception, “TaiwanPlus strives to provide a platform to showcase the diverse, creative culture that flourished under Taiwan’s vibrant democracy. Following the positive reception from the TaiwanPlus Film Festival, which was an online curation of 10 iconic Taiwanese films, the platform now seeks to Bring Taiwan to the World through the country’s dynamic indie music scene,” indicates TaiwanPlus CEO Joanne Tsai.
Produced by TaiwanPlus, “Road to Legacy” is a co-production with Legacy Taipei, a live house institution in Taiwan that has hosted many renowned international and Taiwanese bands since 2009. Executive Producer Tien Tsung Ma says, “Contemporary Taiwanese music ranges from electronic music, rock, folk to hip-hop, and this docuseries is a timely snapshot of Taiwan’s music scene.” Shot over the course of 2.5 years, the docuseries unveils the truest side of these music artists, sharing their personalities, philosophy, and vision.
Among the ten bands featured, Tizzy Bac, ABAO and Namewee have garnered the most international presence. Tizzy Bac was established in 1999, offering a unique style of indie rock by integrating jazz, alternative rock, and electronic elements into their music. While indigenous Taiwanese R&B artist, ABAO, is hailed as a symbol of culture and heritage throughout Taiwan for her unique music. Malaysian artist and musician, Namewee, is known for pop and hip-hop, having garnered a following in East and South-East Asia as a passionate, outspoken activist for injustice and inequality. His work has been banned in China due to his song “Fragile Heart.”
The docuseries will be released in three installments, kicking off with the episodes on Tizzy Bac, 88BALAZ and Nighteentael on January 17th. The remaining episodes will be made available in February (PA PUN BAND, Dadado Huang and Sweet John) and March (Namewee, ABAO, The Next Big Thing and LINION). The full listing of “Road to Legacy” can be found at: https://tw.plus/Kb7nt
To coincide with this celebration of music, TaiwanPlus is also hosting an online campaign to crowd-source 12-sec videos with sound that embodies Taiwan on Instagram. Event details can be found here: https://tw.plus/CNV3b.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220116005075/en/
Contact information
Press:
Sara Lin
Sara.lin@taiwanplus.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of